Business Description
Wakamoto Pharmaceutical Co Ltd
ISIN : JP3991200001
Total Employee Number:
404Description
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.02 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | 0.57 | |||||
Interest Coverage | 134.85 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 2.52 | |||||
Beneish M-Score | -2.09 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4.6 | |||||
3-Year EBITDA Growth Rate | 2.1 | |||||
3-Year EPS without NRI Growth Rate | 19.8 | |||||
3-Year Book Growth Rate | 0.3 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 67.24 | |||||
9-Day RSI | 64.71 | |||||
14-Day RSI | 56.5 | |||||
3-1 Month Momentum % | -28.02 | |||||
6-1 Month Momentum % | -21.04 | |||||
12-1 Month Momentum % | -16.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.48 | |||||
Quick Ratio | 2.07 | |||||
Cash Ratio | 0.72 | |||||
Days Inventory | 245.76 | |||||
Days Sales Outstanding | 108.51 | |||||
Days Payable | 81.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.08 | |||||
Dividend Payout Ratio | 0.53 | |||||
3-Year Dividend Growth Rate | 5.3 | |||||
Forward Dividend Yield % | 1.26 | |||||
5-Year Yield-on-Cost % | 1.08 | |||||
Shareholder Yield % | -0.32 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 47.75 | |||||
Operating Margin % | 2.58 | |||||
Net Margin % | 2.29 | |||||
EBITDA Margin % | 7.08 | |||||
FCF Margin % | -11.52 | |||||
OCF Margin % | -4.91 | |||||
ROE % | 1.94 | |||||
ROA % | 1.47 | |||||
ROIC % | 1.9 | |||||
3-Year ROIIC % | 6.17 | |||||
ROC (Joel Greenblatt) % | 3.22 | |||||
ROCE % | 1.95 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 42.51 | |||||
PE Ratio without NRI | 42.4 | |||||
PS Ratio | 0.98 | |||||
PB Ratio | 0.81 | |||||
Price-to-Tangible-Book | 0.82 | |||||
EV-to-EBIT | 31.14 | |||||
EV-to-EBITDA | 11.47 | |||||
EV-to-Revenue | 0.82 | |||||
EV-to-FCF | -7.08 | |||||
Price-to-GF-Value | 0.87 | |||||
Price-to-Projected-FCF | 1.83 | |||||
Price-to-Median-PS-Value | 1.06 | |||||
Price-to-Graham-Number | 1.24 | |||||
| Price-to-Net-Current-Asset-Value | 1.86 | |||||
Earnings Yield (Greenblatt) % | 3.21 | |||||
FCF Yield % | -11.83 | |||||
Forward Rate of Return (Yacktman) % | -27.11 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Wakamoto Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil 円) | 9,906.84 | ||
| EPS (TTM) (円) | 6.54 | ||
| Beta | -0.4882 | ||
| 3-Year Sharpe Ratio | 0.27 | ||
| 3-Year Sortino Ratio | 0.51 | ||
| Volatility % | 26.22 | ||
| 14-Day RSI | 56.5 | ||
| 14-Day ATR (円) | 6.442434 | ||
| 20-Day SMA (円) | 268.05 | ||
| 12-1 Month Momentum % | -16.44 | ||
| 52-Week Range (円) | 240 - 380 | ||
| Shares Outstanding (Mil) | 34.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Wakamoto Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Wakamoto Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (円) | ||
|---|---|---|---|---|
| JPY 3.500000 Cash Dividend | 2026-03-30 | 359.00 (-1.37%) | ||
| JPY 3.000000 Cash Dividend | 2025-03-28 | 329.00 (-2.08%) |
Show
Entries
Wakamoto Pharmaceutical Co Ltd Frequently Asked Questions
What is Wakamoto Pharmaceutical Co Ltd(TSE:4512)'s stock price today?
The current price of TSE:4512 is 円278.00. The 52 week high of TSE:4512 is 円380.00 and 52 week low is 円240.00.
When is next earnings date of Wakamoto Pharmaceutical Co Ltd(TSE:4512)?
The next earnings date of Wakamoto Pharmaceutical Co Ltd(TSE:4512) is .
Does Wakamoto Pharmaceutical Co Ltd(TSE:4512) pay dividends? If so, how much?
The Dividend Yield %  of Wakamoto Pharmaceutical Co Ltd(TSE:4512) is 1.08% (As of Today), Highest Dividend Payout Ratio of Wakamoto Pharmaceutical Co Ltd(TSE:4512) was 2.03. The lowest was 0.53. And the median was 0.89. The  Forward Dividend Yield % of Wakamoto Pharmaceutical Co Ltd(TSE:4512) is 1.26%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Wakamoto Pharmaceutical Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers